Equity Research Analysts at Shore Capital Reiterated their Hold rating for AstraZeneca PLC (LON:AZN). The Target Price per Share is Set to GBX 5428.00; Shorts at Culp (CULP) Raised By 3.09%

AstraZeneca PLC (LON:AZN) Logo

Culp Inc (NYSE:CULP) had an increase of 3.09% in short interest. CULP’s SI was 123,500 shares in May as released by FINRA. Its up 3.09% from 119,800 shares previously. With 15,100 avg volume, 8 days are for Culp Inc (NYSE:CULP)’s short sellers to cover CULP’s short positions. The SI to Culp Inc’s float is 1.26%. It closed at $31.3 lastly. It is down 0.82% since May 25, 2017 and is downtrending. It has underperformed by 12.37% the S&P500.

Shore Capital currently has a GBX 5428.00 target price per share on the 69.41 billion GBP market cap company or -0.71% downside potential. In analysts report issued on Friday, 25 May, AstraZeneca PLC (LON:AZN) stock had its Hold Rating reconfirmed by research professionals at Shore Capital.

Culp, Inc. manufacturers, sources, markets, and sells mattress fabrics, sewn covers, and cut and sewn kits for use in mattresses, foundations, and other bedding products in North America, the Far East, Asia, and internationally. The company has market cap of $389.69 million. It operates through two divisions, Mattress Fabrics and Upholstery Fabrics. It has a 27.5 P/E ratio. The Mattress Fabrics segment offers woven jacquard, knitted, and converted fabrics for use in the production of bedding products, including mattresses, box springs, foundations, and bed components.

AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. The company has market cap of 69.41 billion GBP. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. It has a 23.12 P/E ratio. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

The stock increased 0.96% or GBX 52 during the last trading session, reaching GBX 5480. About 378,649 shares traded. AstraZeneca PLC (LON:AZN) has 0.00% since May 25, 2017 and is . It has underperformed by 11.55% the S&P500.

Culp, Inc. (NYSE:CULP) Institutional Positions Chart